FDA To Re-Evaluate Safety Of NMEs In Pilot Postmarket Monitoring Program
Executive Summary
FDA will prepare safety profiles for several new molecular entities, using data from the first year of post-market experience, under a pilot program that is part of the agency's response to the Institute of Medicine's recommendations for improving drug safety in the United States
You may also be interested in...
FDA’s Postmarket Drug Safety Pilot Will Consider Between Five And 10 Drugs
FDA expects to begin in March to develop the first safety profile under a pilot program for postmarket monitoring of new molecular entities
FDA’s Postmarket Drug Safety Pilot Will Consider Between Five And 10 Drugs
FDA expects to begin in March to develop the first safety profile under a pilot program for postmarket monitoring of new molecular entities
Janet Woodcock’s Mission: Predict Adverse Events, ID Them After They Happen
FDA's drug safety reforms in response to the Institute of Medicine's report include emphasizing the newly created position of chief medical officer